These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 9441281)

  • 1. [18F-fluorodeoxyglucose PET in ovarian carcinoma: methodology and preliminary results].
    Zimny M; Schröder W; Wolters S; Cremerius U; Rath W; Büll U
    Nuklearmedizin; 1997 Oct; 36(7):228-33. PubMed ID: 9441281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Preoperative assessment of asymptomatic adnexal tumors by positron emission tomography and F 18 fluorodeoxyglucose].
    Fenchel S; Kotzerke J; Stöhr I; Grab D; Nüssle K; Rieber A; Kreienberg R; Brambs HJ; Reske SN
    Nuklearmedizin; 1999; 38(4):101-7. PubMed ID: 10392374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer.
    Zimny M; Siggelkow W; Schröder W; Nowak B; Biemann S; Rath W; Buell U
    Gynecol Oncol; 2001 Nov; 83(2):310-5. PubMed ID: 11606090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic value of PET/CT is similar to that of conventional MRI and even better for detecting small peritoneal implants in patients with recurrent ovarian cancer.
    Sanli Y; Turkmen C; Bakir B; Iyibozkurt C; Ozel S; Has D; Yilmaz E; Topuz S; Yavuz E; Unal SN; Mudun A
    Nucl Med Commun; 2012 May; 33(5):509-15. PubMed ID: 22357440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Metabolic characterization of ovarian tumors with positron-emission tomography and F-18 fluorodeoxyglucose].
    Römer W; Avril N; Dose J; Ziegler S; Kuhn W; Herz M; Jänicke F; Schwaiger M
    Rofo; 1997 Jan; 166(1):62-8. PubMed ID: 9072107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of positron emission tomography with tracer 18-fluorodeoxyglucose in addition to magnetic resonance imaging in the diagnosis of ovarian cancer in selected women after ultrasonography.
    Kawahara K; Yoshida Y; Kurokawa T; Suzuki Y; Nagahara K; Tsuchida T; Okazawa H; Fujibayashi Y; Yonekura Y; Kotsuji F
    J Comput Assist Tomogr; 2004; 28(4):505-16. PubMed ID: 15232382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
    Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
    Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer.
    Hebel CB; Behrendt FF; Heinzel A; Krohn T; Mottaghy FM; Bauerschlag DO; Verburg FA
    Eur J Radiol; 2014 Mar; 83(3):463-7. PubMed ID: 24368010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of 18F-FDG PET with bladder irrigation in patients with uterine and ovarian tumors.
    Koyama K; Okamura T; Kawabe J; Ozawa N; Torii K; Umesaki N; Miyama M; Ochi H; Yamada R
    J Nucl Med; 2003 Mar; 44(3):353-8. PubMed ID: 12621000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer.
    Nakamoto Y; Saga T; Ishimori T; Mamede M; Togashi K; Higuchi T; Mandai M; Fujii S; Sakahara H; Konishi J
    AJR Am J Roentgenol; 2001 Jun; 176(6):1449-54. PubMed ID: 11373212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic evaluation of malignant head and neck cancer by F-18-FDG PET compared to CT/MRI.
    Nowak B; Di Martino E; Jänicke S; Cremerius U; Adam G; Zimny M; Reinartz P; Büll U
    Nuklearmedizin; 1999; 38(8):312-8. PubMed ID: 10615664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology.
    Castellucci P; Perrone AM; Picchio M; Ghi T; Farsad M; Nanni C; Messa C; Meriggiola MC; Pelusi G; Al-Nahhas A; Rubello D; Fazio F; Fanti S
    Nucl Med Commun; 2007 Aug; 28(8):589-95. PubMed ID: 17625380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy.
    Rose PG; Faulhaber P; Miraldi F; Abdul-Karim FW
    Gynecol Oncol; 2001 Jul; 82(1):17-21. PubMed ID: 11426956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings.
    Fenchel S; Grab D; Nuessle K; Kotzerke J; Rieber A; Kreienberg R; Brambs HJ; Reske SN
    Radiology; 2002 Jun; 223(3):780-8. PubMed ID: 12034950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma.
    Kim S; Chung JK; Kang SB; Kim MH; Jeong JM; Lee DS; Lee MC
    Eur J Nucl Med Mol Imaging; 2004 Feb; 31(2):196-201. PubMed ID: 15129701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Positron emission tomography (PET) in malignant ovarian tumors].
    Fularz M; Adamiak P; Czepczyński R; Jarzabek-Bielecka G; Kedzia W; Ruchała M
    Ginekol Pol; 2013 Aug; 84(8):720-5. PubMed ID: 24191507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET-CT in recurrent ovarian cancer: impact on treatment planning.
    Lenhard MS; Burges A; Johnson TR; Stieber P; Kümper C; Ditsch N; Linke R; Friese K
    Anticancer Res; 2008; 28(4C):2303-8. PubMed ID: 18751410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of whole body positron emission tomography (PET) with 18F-fluoro-2-deoxyglucose (FDG) to detect recurrent ovarian cancer based on asymptomatically elevated serum levels of tumor marker.
    Chang WC; Hung YC; Kao CH; Yen RF; Shen YY; Lin CC
    Neoplasma; 2002; 49(5):329-33. PubMed ID: 12458332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of PET/CT in the diagnosis of recurrent ovarian cancer depending on CA 125 serum level.
    Fularz M; Adamiak P; Czepczyński R; Jarząbek-Bielecka G; Rewers A; Kędzia W; Ruchała M
    Nuklearmedizin; 2015; 54(4):158-62. PubMed ID: 26076719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.